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OBJECTIVES: Chronic thromboembolic pulmonary hypertension is one of the most prevalent forms of pulmonary
hypertension and is a major complication of acute pulmonary embolism. One mainstay of chronic throm-
boembolic pulmonary hypertension treatment is lifelong anticoagulation. The recent advent of direct oral
anticoagulants for acute pulmonary embolism treatment has provided a viable and effective alternative for
treating this condition. However, little is known about the efficacy of this new class of drugs for treating chronic
thromboembolic pulmonary hypertension. We aimed to evaluate the safety and efficacy of direct oral anti-
coagulants in the treatment of chronic thromboembolic pulmonary hypertension.
METHODS: A cohort of chronic thromboembolic pulmonary hypertension patients who initiated treatment with
direct oral anticoagulants between June 2015 and November 2016 were enrolled in this study.
RESULTS: Sixteen patients used rivaroxaban, three used dabigatran and one used apixaban for a mean follow-up
of 20.9 months. The mean age was 51 years, and eighteen patients were classified as functional class II/III. Eight
patients underwent a pulmonary endarterectomy and exhibited clinical, hemodynamic and functional improve-
ment and currently continue to use direct oral anticoagulants. No episode of venous thromboembolism
recurrence was identified during the follow-up period, but there was one episode of major bleeding after a
traumatic fall.
CONCLUSIONS: Although direct oral anticoagulants appear to be a safe and effective alternative for treating
chronic thromboembolic pulmonary hypertension, larger studies are needed to support their routine use.
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’ INTRODUCTION
Acute pulmonary embolism (PE) is a highly prevalent
condition, and with up to 3 million associated deaths per year,
it is the third most common cause of cardiovascular death in
the world (1). However, currently, systemic anticoagulation is
an effective therapy for acute PE. Since the 60s, several studies
have demonstrated the impact of intravenous or subcuta-
neous anticoagulation on mortality of acute PE patients and
the capacity of anticoagulation for preventing recurrence (2,3).
Oral vitamin K antagonists (VKA) were also success-
fully evaluated for use in anticoagulation therapy for acute
PE (4). Nevertheless, the pharmacological properties of VKA
pose several challenges for their long-term use, which
led researchers to pursue newer, safer and better oral
anticoagulation alternatives for treating general and, in partic-
ular, acute PE. Direct oral anticoagulants (DOACs) (dabigatran,
rivaroxaban, apixaban and edoxaban) have recently been
shown to be an effective and a possibly safer alternative to
conventional anticoagulation agents (5) in the treatment of
acute PE. These new drugs are now the first choice for treating
acute PE unrelated to malignancy (6). Nevertheless, the efficacy
and safety of DOACs have not been studied in one of the
most severe complications of acute PE, chronic thromboembolic
pulmonary hypertension (CTEPH).
CTEPH is a serious, potentially fatal disease and one of
the most prevalent forms of pulmonary hypertension (PH),
defined by the presence of mean pulmonary artery pressure
X 25 mmHg (7,8). Data suggest that 0.1 to 8.8 % of acute PE
patients may develop CTEPH (9). Known risk factors for the
chronicity of PE are chronic inflammatory and infectious
diseases, high recurrence rates of venous thromboembolism
(VTE) and genetic predisposition (7).
One of the mainstays of CTEPH therapy is lifelong anti-
coagulation, for which VKA are routinely recommended (10).
However, whether the benefits of DOACs that were identified
in acute PE patients are also present in the CTEPH popula-
tion has yet to be demonstrated.
We report a cohort of 20 CTEPH patients treated with
DOACs between June 2015 and November 2016.DOI: 10.6061/clinics/2018/e216
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In this study, sixteen patients used rivaroxaban, three
patients used dabigatran, and one patient used apixaban.
Demographic and functional data are shown in Table 1. The
median time of DOAC use was 20.9 months.
In eight patients, DOACs were used before and after
pulmonary endarterectomy (PEA; also known as pulmonary
thromboendarterectomy or PTE), which is the main ther-
apeutic intervention for CTEPH (11). However, the remaining
12 patients had contraindications for the surgical procedure
or were on a waiting list.
No episode of VTE recurrence was identified during the
follow-up period. Concerning safety, there was one episode
of major bleeding after a traumatic fall that resulted in
the death of the patient. Another patient died during the
immediate postoperative period of PEA, but there was no
association with the use of DOAC.
’ DISCUSSION
In the present study, DOACs were successfully used in
CTEPH patients without any evidence of VTE recurrence
and with low rates of major bleeding, suggesting that DOACs
are a secure and effective option for anticoagulation therapy
for CTEPH.
CTEPH is a progressive disease believed to be related to
inadequate dissolution of an acute thrombus, followed by its
fibrotic organization. A fundamental step in CTEPH treat-
ment is lifelong anticoagulation, and thus, current guidelines
recommend the use of VKA for this purpose. Nevertheless,
the long-term use of VKA is particularly challenging due
to the pharmacological properties of these drugs, such as
narrow therapeutic range, several drug and food interactions
and the continuous need for monitoring. DOACs have
demonstrated a number of advantages over the use of VKA
in several conditions. Clinical trials recently demonstrated
that these new drugs are at least as effective as and possibly
safer than VKA in managing acute lung thrombosis (12).
Nevertheless, data regarding the safety and efficacy of DOACs
in the CTEPH population are still lacking.
Bleeding is the most feared adverse effect of any anti-
coagulation treatment. In this case series, one patient presented
significant bleeding related to trauma that resulted in death,
but no recurrence of PE was identified during the follow-up
period. Of note, the use of DOACs did not interfere with
surgery or the postoperative follow-up period.
This study is a single-center case series with all the
associated intrinsic limitations of such an investigation.
Patients were neither randomized nor VKA-controlled.
Nevertheless, our results are promising and suggest that
DOACs are a safe and effective alternative therapy for life-
long anticoagulation of CTEPH patients, thus emphasizing
the need for prospective, randomized, multicenter trials to
establish the routine use of DOACs in CTEPH patients.
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Table 1 - Patient demographic and clinical features
Gender (M:F) 8:12
Age (years) 51±16
BMI 28±4
Functional class
I
II 10
III 8
IV 2
Hemodynamic data
mPAP (mmHg) 53±10
PAOP (mmHg) 14±5
CO (L/min) 3.7±1.2
PVR (WU) 11±4
BNP (pg/ml) 265±219
6MWT (m) 359±118
DOAC
Apixaban 1
Dabigatran 3
Rivaroxaban 16
Duration of use (month) 20±14
PEA: pulmonary endarterectomy, M: male, F: female, cm: centimeters,
BMI: body mass index, mPAP: mean pulmonary arterial pressure, PAOP:
pulmonary artery occlusion pressure, CO: cardiac output, PVR: pulmonary
vascular resistance, BNP: B-type natriuretic peptide, 6MWT: six-minute
walking test, DOAC: direct oral anticoagulant.
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